Urinary CTGF in Benign Prostatic Obstruction

Starting soon · Has a placebo group

Conditions studied: Benign Prostatic Hyperplasia, Bladder Outlet Obstruction, Lower Urinary Tract Symptom

In brief

Benign prostatic obstruction (BPO) is one of the most common causes of bladder outlet obstruction (BOO) and may lead to progressive structural and functional alterations in the bladder over time. Prolonged obstruction triggers a bladder remodeling process characterized by detrusor hypertrophy, ischemia-reperfusion injury, smooth muscle loss, and progressive fibrosis. These pathological changes may result in impaired detrusor contractility, increased post-void residual volume, and suboptimal functional recovery following surgical treatment. Connective tissue growth factor (CTGF) is a matricellular protein that plays a key role in fibrogenesis and is markedly upregulated under hypoxic, ischemia-reperfusion, and inflammatory conditions. Experimental and cellular studies have demonstrated that CTGF promotes fibroblast proliferation, extracellular matrix production, and collagen deposition, thereby contributing to bladder fibrosis. Increased CTGF expression has also been associated with fibrotic differentiation of bladder smooth muscle cells. The aim of this observational study is to evaluate the relationship between urinary CTGF levels, bladder fibrosis, and functional response to surgical treatment in patients with benign prostatic obstruction. Preoperative urinary CTGF levels will be assessed and correlated with postoperative functional outcomes and clinical improvement. This study aims to determine whether urinary CTGF may serve as a non-invasive biomarker of bladder fibrosis and a potential predictor of surgical treatment response in patients with BPO.

Key facts

Study ID

NCT07416981

Run by

Tarik Emre Sener

People needed

50

Starts

2026-04-01

Expected to finish

2026-12-01

Last updated by the study team

2026-02-18

Who can join

Age: 40 and older. Sex: male. Healthy volunteers: not accepted.

You may qualify if…

• Male patients aged > 40 years
• Diagnosis of benign prostatic obstruction (BPO), with or without an indwelling catheter
• Patients with an indication for surgical treatment according to EAU guidelines

You may not qualify if…

• Age < 40 years
• Female sex
• Prostate-specific antigen (PSA) > 2.5 ng/mL
• History of endoscopic urological intervention
• Previous urogenital malignancy or urological surgery
• Diabetes mellitus
• Urethral stricture
• History of pelvic radiotherapy and/or chemotherapy
• Patients performing clean intermittent catheterization
• Neurological diseases causing secondary urinary symptoms (e.g., spinal cord injury, stroke, multiple sclerosis, Parkinson's disease)
• History of spinal surgery
• History of colorectal cancer or previous colorectal surgery

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.